OptiPin
Cagrilintide: calculator, dosing & the facts
A long-acting synthetic peptide that mimics amylin, a hormone co-secreted with insulin. Acts as a dual agonist for amylin and calcitonin receptors. Often studied in combination with Semaglutide (CagriSema) or Retatrutide (CagriReta) for enhanced weight loss. This is an evidence-graded reference – what it is, what it's used for, typical reported dosing, half-life, side effects, and how to track it. It is educational, not medical advice or a recommendation to use a research compound.
- • Cagrilintide – Fat loss. A long-acting synthetic peptide that mimics amylin, a hormone co-secreted with insulin.
- • Commonly used for obesity treatment, type 2 diabetes management, enhanced satiety and appetite reduction.
- • Half-life: Extended half-life via fatty acid acylation.
- • Status: Research use only · not FDA-approved – an educational reference, not a dose protocol or sourcing advice.
Cagrilintide calculator
Vial, water and dose in, syringe units out. Runs in your browser; nothing is sent anywhere.
Arithmetic only. The starting figures are the worked example in the reconstitution note on this page, not a dose recommendation. A U-40 syringe reads differently – see the syringe units chart. For a reusable pen, use the peptide pen calculator.
What Cagrilintide is
A long-acting synthetic peptide that mimics amylin, a hormone co-secreted with insulin. Acts as a dual agonist for amylin and calcitonin receptors. Often studied in combination with Semaglutide (CagriSema) or Retatrutide (CagriReta) for enhanced weight loss.
What Cagrilintide is used for
- • Obesity treatment
- • Type 2 diabetes management
- • Enhanced satiety and appetite reduction
- • Slower gastric emptying
- • Blood glucose stabilization
- • Combination therapy with GLP-1 agonists
These are reported/community uses, not proven clinical outcomes. Most research peptides have limited human trial data behind such claims.
Typical reported dosing
| Injectable | Weeks 1–4: 0.25mg (10 units) once weekly. Weeks 5–8: 0.5mg (20 units) weekly. Weeks 9–12: 1.0mg (40 units) weekly. Weeks 13–16: 1.7mg (68 units) weekly. Subcutaneous injection. |
Presented as commonly-reported patterns for information only – not a dose recommendation. Cagrilintide dosing is a decision for a qualified clinician.
Reconstitution
Reconstitute 5mg vial with 2mL BAC water. 0.25mg = 10 units, 0.5mg = 20 units, 1.0mg = 40 units, 1.7mg = 68 units. The arithmetic is the same for any peptide: concentration = vial mg ÷ water mL, and on a U-100 syringe 100 units = 1 mL. Compute your own vial with the calculator at the top of this page.
Cagrilintide dose-to-units chart
| Vial + water | Concentration | 1 unit holds | 0.25 mg | 0.5 mg | 1 mg | 1.7 mg |
|---|---|---|---|---|---|---|
| 5 mg + 2 mL | 2.5 mg/mL | 25 mcg | 10 u | 20 u | 40 u | 68 u |
Units on a U-100 insulin syringe, where 100 units = 1 mL. Red means under 5 units (a one-unit misread is a 20% dose error or worse) or over 100 (more than a 1 mL syringe holds). The dose columns are the worked examples in the reconstitution note above, shown as arithmetic, not as a recommendation.
Half-life & cycling
Half-life: Extended half-life via fatty acid acylation. Half-life drives dosing frequency and how quickly the compound clears – see it plotted on the Cagrilintide half-life calculator.
Cycling
Continuous use. Doses escalated every 4 weeks to reduce side effects like nausea.
Side effects & warnings
- an injection site that turns red, hot or hard, spreads, weeps, or comes with a fever – same-day medical care – research-grade material carries no sterility guarantee, so abscess and cellulitis are the documented consequence
- swelling of the lips, tongue or throat, trouble breathing, or widespread hives after a dose – emergency care
- severe abdominal pain that bores through to the back and does not settle – urgent assessment for pancreatitis
- vomiting that stops you keeping fluids down – urgent care – dehydration is the common reason people on these compounds are admitted
- shaking, sweating, confusion or a racing heart, especially alongside insulin or a sulfonylurea – treat for low blood sugar and seek advice
- • Nausea
- • Gastrointestinal side effects
- • Appetite suppression
- • Expected similar to GLP-1 medications
Research use only. Often used in combination therapy with GLP-1 agonists for enhanced weight loss and glycemic control. Gradual dose escalation recommended to minimize side effects.
Tracking Cagrilintide in OptiPin
If you're tracking a Cagrilintide protocol, OptiPin logs each dose with reminders and site rotation, charts the outcome you care about over your dose timeline, keeps per-vial inventory with runout warnings, and (where relevant) does the reconstitution math – all on-device, no account.
Log doses, outcomes & vials in OptiPin
Reminders, outcome-over-dose charts, vial runout warnings, and built-in reconstitution math – all on-device.
Download on the App StoreFAQ
What is Cagrilintide?
A long-acting synthetic peptide that mimics amylin, a hormone co-secreted with insulin. Acts as a dual agonist for amylin and calcitonin receptors. Often studied in combination with Semaglutide (CagriSema) or Retatrutide (CagriReta) for enhanced weight loss.
How many units is 0.25 mg of Cagrilintide?
On a U-100 insulin syringe, from a 5 mg vial with 2 mL of water it is 10 units (0.1 mL). The answer depends entirely on how much water went into the vial, so check your own vial with the calculator on this page. This is arithmetic, not a dose recommendation.
What is Cagrilintide used for?
Commonly discussed uses include: obesity treatment, type 2 diabetes management, enhanced satiety and appetite reduction, slower gastric emptying, blood glucose stabilization, combination therapy with glp-1 agonists. These are reported uses, not proven outcomes or a recommendation.
How is Cagrilintide dosed?
Commonly reported dosing: Injectable – Weeks 1–4: 0.25mg (10 units) once weekly. Weeks 5–8: 0.5mg (20 units) weekly. Weeks 9–12: 1.0mg (40 units) weekly. Weeks 13–16: 1.7mg (68 units) weekly. Subcutaneous injection.. This reflects patterns discussed in the community and is presented for information only, not as a dose recommendation – Cagrilintide is not an approved medicine and dosing should involve a qualified clinician.
How do you reconstitute Cagrilintide?
Reconstitute 5mg vial with 2mL BAC water. 0.25mg = 10 units, 0.5mg = 20 units, 1.0mg = 40 units, 1.7mg = 68 units. On a U-100 syringe, 100 units = 1 mL. Concentrations vary by vial, so compute from your own vial with a reconstitution calculator.
What is Cagrilintide's half-life?
Extended half-life via fatty acid acylation. Half-life shapes how often it is dosed and how quickly it clears.
What are Cagrilintide's side effects?
Reported effects include: nausea, gastrointestinal side effects, appetite suppression, expected similar to glp-1 medications. Because it is a research compound, its safety profile is not fully characterized; discuss risks with a clinician.
Evidence & further reading
- Search the peer-reviewed literature for Cagrilintide on PubMed (entry point to the primary evidence base, not a specific citation).
- Cagrilintide on ClinicalTrials.gov – registered human trials, if any.
- US FDA / 503A compounding status of research peptides (2026).
- OptiPin peptides guide – categories, evidence grading, and how to run a protocol honestly.
Related
Eloralintide · Frag 176–191 · MOTS-C · SLU-PP-332 · Tirzepatide · Reconstitution calculator · All peptides